海藻酸钙/聚精氨酸微胶囊的制备及其生物相容性

Preparation and biocompatibility of alginate/poly (L-arginine) microcapsules

以海藻酸盐、聚精氨酸为壁材,采用高压静电法制备了球形度好、表面光洁、粒径均匀的新型药物载体——海藻酸钙/聚精氨酸微胶囊。参照医疗器械生物学评价标准,对其生物相容性进行了研究。细胞毒性试验结果显示,当海藻酸钙/聚精氨酸微胶囊的含量为0.1、0.5、1.0 mg/mL时,微胶囊对L929细胞生长无明显抑制作用,海藻酸钙/聚精氨酸微胶囊浸提产物在10.0 mg/mL时仍无细胞毒性作用。海藻酸钙/聚精氨酸微胶囊不引起急性全身毒性反应,不引起溶血反应。通过本组试验可见,采用高压静电法制备的药物载体——海藻酸钙/聚精氨酸微胶囊具有较好的生物相容性,具有开发和应用价值。

A novel drug carrier based on alginate and poly-L-arginine was fabricated. The alginate/poly （L- arginine） microcapsules with good sphericity, smooth surface and well-proportioned particle size were prepared by the high voltage electrostatic method. According to the standard for the biological evaluation of medical devices, the biocompatibility of alginate/poly（L-arginine） microcapsules was studied. The cytotoxicity studies show that the alginate/poly（L-arginine） microcapsules have no significant growth inhibition effect on L929 cells when they were used at 0.1, 0.5, 1.0 mg/mL. The extract productions of the alginate/poly（L-arginine） microcapsules do not show cytotoxic effect even at 10.0 mg/mL. The alginate/poly（L-arginine） microcapsules have no acute systemic toxicity and no hemolytic reaction. All results indicate that the alginate/poly（L-arginine） microcapsules, prepared by the high voltage electrostatic method, have acceptable biocompatibility and might be an appropriate candidate for macromolecule drug delivery, and it is worthy of a further research.